IGF-1 LR3 vs Ipamorelin

Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.

IGF-1-LR3 (Long Arg3 IGF-1) is a synthetic 83-amino-acid analog of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that substantially reduces binding to IGF-binding proteins (IGFBPs), resulting in a biological half-life approximately 120 times longer than native IGF-1 and theoretically greater receptor availability in peripheral tissues. The reduced IGFBP affinity means a higher proportion of circulating IGF-1-LR3 remains unbound and potentially bioactive; in vitro cell proliferation studies and animal models suggest amplified anabolic signaling relative to equimolar native IGF-1, and the compound is widely used as a research reagent in cell culture for controlled IGF-1R stimulation without the confounding effects of endogenous binding protein dynamics. No human pharmacokinetic, safety, or efficacy studies of IGF-1-LR3 have been published in PubMed-indexed journals; the indexed scientific literature consists of in vitro proliferation studies, animal metabolic research, and anti-doping detection methods — a complete absence of clinical data supporting or characterizing its use in humans. IGF-1-LR3 has no FDA approval or regulatory approval in any jurisdiction; it is a research laboratory reagent and non-approved analog available through research chemical suppliers, and the complete absence of published human data means its pharmacological behavior, tissue distribution, and safety profile in humans are entirely uncharacterized. IGF-1 LR3 in research contexts: as a laboratory reagent, IGF-1-LR3 is used at nanomolar concentrations in cell culture assays to stimulate IGF-1 receptor signaling. The extended half-life (approximately 20–30 hours compared to native IGF-1's 15 minutes) is the primary reason for its use in research settings requiring sustained IGF-1R activation. In animal pharmacology studies, doses vary widely by species and model; these cannot be directly extrapolated to human dosing, and no safe or effective human dose has been established. Its extended half-life relative to native IGF-1 is also the property most frequently cited in anti-doping detection literature, where the compound has been identified in biological samples from competitive athletes. The absence of any human clinical data distinguishes IGF-1-LR3 from growth hormone secretagogues such as sermorelin, ipamorelin, or MK-677, which have documented human pharmacological profiles. Providers offering researched GH-axis peptides with clinical datasets are listed in the PeptideBase directory.

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue that acts as a ghrelin receptor (GHS-R1a) agonist, valued in research for its selectivity for GH release with minimal concurrent stimulation of cortisol, prolactin, or ACTH compared to earlier GH-releasing peptides such as GHRP-2 and GHRP-6. Ipamorelin stimulates pulsatile GH secretion from pituitary somatotrophs through ghrelin receptor signaling; its selective endocrine profile was characterized preclinically and distinguishes it from less selective GHRPs, making it a widely used tool compound in GH secretagogue research and the subject of exploratory clinical development for GI motility applications. The only indexed Phase II human trial of ipamorelin examined its effects on postoperative ileus in bowel resection patients, demonstrating GI motility improvements consistent with its enteric GHS-R1a activity; no published human data addresses its effects on GH secretion, body composition, or performance outcomes in the contexts for which it is commonly used as a research compound. Ipamorelin has no FDA approval for any indication; it is a research compound with well-characterized preclinical pharmacology and a single published human trial in a GI context, and claims regarding its use for muscle gain, fat loss, or anti-aging purposes are not supported by published clinical evidence. Ipamorelin is frequently studied in combination with CJC-1295 (a GHRH analogue), with the rationale that CJC-1295 extends the GHRH pulse window while ipamorelin provides selective GHS-R1a stimulation without additional cortisol or prolactin burden. The CJC-1295 ipamorelin combination is among the most commonly researched GH secretagogue pairings in both the research literature and in compounded clinical protocols, and both compounds are available through telehealth providers and compounding pharmacies in the PeptideBase directory. A triple combination of sermorelin, ipamorelin, and CJC-1295 has also been explored in research contexts as a multi-pathway approach to GH axis support, though no published human trial evidence supports this specific combination. Ipamorelin's side effect profile in preclinical and limited clinical research is considered favorable relative to earlier GHRPs. Unlike GHRP-2 and GHRP-6, which produce dose-dependent elevations in cortisol, prolactin, and ACTH, ipamorelin selectively stimulates GH release with minimal effect on these hormones at standard research doses — its selectivity was a primary design objective in its development. Commonly reported observations in research contexts include transient water retention (attributed to IGF-1-mediated sodium reabsorption at higher doses), mild injection-site discomfort, and occasionally headache or flushing shortly after administration, consistent with the acute GH pulse. Long-term use considerations include potential receptor desensitization with continuous daily dosing, which is why cycling protocols (e.g., 5 days on, 2 days off, or monthly off-cycles) are common in research designs. At doses substantially exceeding research norms, GH-class effects such as peripheral paresthesia, joint stiffness, and carpal tunnel-type symptoms have been observed — consistent with GH-excess effects across secretagogue and exogenous HGH literature. Ipamorelin's long-term safety profile in humans has not been established through controlled clinical trials; all available safety observations derive from preclinical studies and the single published Phase II GI motility trial, which was short-duration and not designed to assess endocrine safety endpoints.